Drugs used in this study were recombinant murine
sTRAIL/Apo2L (Peprotech; NJ, USA),
murine TNFα (Peprotech), Debio1143/AT-406 (Selleck Chemicals; Texas, USA),
LCL161 (Selleck Chemicals),
SM-164 (ApexBio; Texas, USA),
Birinapant (ApexBio), BV6 (ApexBio), GDC-0512 (Selleck),
doxorubicin (Sigma-Aldrich; MO, USA) and
cisplatin (Sigma-Aldrich). The following antibodies were used:
anti-cIAP1 (Enzo Life sciences; NY, USA), anti-cIAP2 (R&D systems; MN, USA), anti-XIAP (MBL International; MA, USA),
anti-FADD (Abcam; Cambridge, UK),
anti-TNFR1 (Abcam), anti-TRAIL-R2 (R&D systems),
anti-caspase-3 (BD Biosciences; NJ, USA),
anti-caspase-8 (Abcam),
anti-RIPK1 (BD Biosciences),
anti-RIPK3 (ProSci; CA, USA), anti-MLKL1 (Abcam), anti-phosphoS345-MLKL (Abcam), anti-CYLD (Thermo Fisher Scientific; Massachusetts, USA), anti-crmA (Santa Cruz Biotechnology; Texas, USA), rabbit anti-GFP (polyclonal in-house antibody),
goat anti-rabbit FITC (Merck Millipore; MA, USA), rabbit anti-goat-FITC (Thermo Fisher Scientific),
mouse anti-GAPDH (Merck Millipore), donkey anti-rabbit HRP conjugated antibody (GE Healthcare Life Sciences; NJ, USA), goat anti-rat HRP conjugated antibody (GE Healthcare Life Sciences), and
rabbit anti-mouse-HRP conjugated antibody (Sigma).
Shekhar T.M., Miles M.A., Gupte A., Taylor S., Tascone B., Walkley C.R, & Hawkins C.J. (2016). IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα. Oncotarget, 7(23), 33866-33886.